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High serum parathyroid hormone levels are associated
with vascular calcification. Cinacalcet is a calcimimetic agent
that inhibits parathyroid hormone secretion and is used to
treat patients with secondary hyperparathyroidism. Here
we measured the effects of oral cinacalcet on calcification
of the aorta and heart in rats with a remnant kidney
(5/6 nephrectomy) model of uremia that were fed a
high-phosphate diet containing lactose to accelerate the
process of aortic calcification. Alizarin red staining showed
that the smooth muscle in the aortic arch of rats with a
remnant kidney was calcified. The tissue levels of calcium and
phosphorus in the aorta and hearts of these rats were
significantly increased compared to sham-operated rats.
Expression of the osteoblastic lineage genes osteocalcin,
osteopontin and runt-related gene 2 were also increased
in the aorta of these rats. Cinacalcet suppressed these
calcification-related changes by reducing serum parathyroid
hormone, calcium, phosphorus, and the calcium-phosphorus
product. Parathyroidectomy also suppressed calcification in
this model. We suggest that cinacalcet inhibits calcification of
the aorta and heart in uremic patients with secondary
hyperparathyroidism by decreasing serum parathyroid
hormone levels.
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Aortic calcification is associated with increased morbidity
and mortality in patients with chronic kidney disease.1–6
Elevation of serum calcium (Ca), phosphorus (P), and
Ca P product are considered the main risk factors for aortic
calcification.7,8 Secondary hyperparathyroidism (2HTP) is
also often observed in patients with advanced chronic kidney
disease and in dialysis patients. Whether parathyroid
hormone (PTH) has beneficial or detrimental effects on
vascular calcification is still the subject of some debate. High
serum PTH levels, which promote elevation of serum Ca, P,
and Ca P product, have been associated with higher
mortality in 2HPT patients.9 It has been reported that high
serum PTH levels are associated with severity of coronary Ca
deposits in hemodialysis patients.10 Neves et al.11 also
reported that high PTH levels induce both high bone
turnover and aortic calcification independently of uremia.
In contrast, emerging evidence suggests a protective effect of
PTH against vascular calcification: a bioactive fragment of
PTH, 1–34 PTH, has also been demonstrated to have
inhibitory effects on calcification in low-density lipoprotein
receptor knockout mice.12
Cinacalcet HCl (cinacalcet) is a novel therapeutic agent for
the treatment of dialysis patients diagnosed with 2HPT.
Cinacalcet is a calcimimetic compound and inhibits PTH
secretion from the parathyroid cells by activation of the Ca
receptor.13,14 We have previously demonstrated that cinacal-
cet has direct suppressive effects on PTH secretion in
cultured human parathyroid cells derived from patients with
2HPT.15 In previous clinical studies, cinacalcet also has been
reported to suppress serum PTH, Ca, P, and Ca P product
in patients with 2HPT.16–18 It has been further reported that
cinacalcet does not induce aortic calcification in nephrecto-
mized (NX) rats.19 Recently, Lopez et al.20 reported that
the calcimimetic compound AMG 641 diminished 1,25-
dihydroxyvitamin D3 (1,25(OH)2VD)-induced aortic calcifi-
cation in 5/6 NX rats. However, no prior study has examined
whether cinacalcet can suppress aortic calcification that is
caused by the progression of 2HPT.
In the present study, we examined the effects of cinacalcet
on the incidence of aortic and heart calcification in NX
uremic rats fed high-phosphate chow containing 20% lactose
(HP-lactose chow). In addition, the effects of parathyroi-
dectomy (PTX) were examined in this animal model to
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further elucidate the role of PTH during the development of
both aortic calcification and heart calcification.
RESULTS
Serum biochemistry
During the treatment period of this study, three rats died in
the NX-vehicle-treated group, but no deaths occurred in the
sham-operated group. One animal died in the NX-cinacalcet-
treated group (15 mg/kg); the cause was thought to be due to
asphyxia by endotracheal administration failure. No deaths
related to treatment with cinacalcet were observed. At the end
of the current study time frame, body weights were found to
have decreased significantly in NX rats compared with sham-
operated rats (data not shown). There were no differences in
body weights of NX-vehicle rats and those treated with
cinacalcet.
Table 1 shows the results of serum biochemical analyses at
the end of the study period on day 41 or 42 post-treatment.
Compared with the sham-operated rats, NX rats developed
uremia, as evidenced by significant increases in serum
creatinine (Cr) and blood urea nitrogen (BUN) levels. The
serum Cr and BUN levels tended to be maintained at low
levels following cinacalcet treatment, compared with those of
vehicle controls, but the differences were not statistically
significant. Serum Ca levels decreased, whereas serum
phosphate levels increased in the NX-vehicle-treated group
compared with the sham-operated group. The serum Ca P
product, which is thought to be a risk factor for aortic
calcification, also increased in the NX-vehicle-treated group.
Cinacalcet treatment was found to decrease serum Ca
levels significantly after 90 min at both dosages. The serum P
levels and Ca P product showed a trend towards a decrease
following cinacalcet treatment at both 90 min and 24 h after
administration. The serum PTH and osteocalcin levels were
found to be elevated in the NX-vehicle-treated group
compared with the sham-operated group. In contrast, serum
PTH levels were significantly decreased at 90 min after
administration in both cinacalcet-treated groups compared
with the NX-vehicle-treated group. The serum osteocalcin
levels showed a trend towards a dose-dependent decrease by
cinacalcet treatment. Although there was no significant
difference, the serum 1,25(OH)2VD levels also showed a
trend towards a dose-dependent decrease by cinacalcet
treatment.
Tissue Ca and P content
In the NX-vehicle-treated group, tissue Ca and P content in
the aorta was significantly increased compared with the
baseline values measured in the NX group (Figure 1). At the
end of the study period, the Ca and P levels in the aorta were
found to have increased approximately 80- and 10-fold,
Table 1 | Serum biochemical measurements (for cinacalcet study)
Sham NX control NX+cinacalcet (5 mg/kg) NX+cinacalcet (15 mg/kg)
90 min 24 h 90 min 24 h 90 min 24 h 90 min 24 h
Ca (mg/100 ml) 9.2±0.2 9.5±0.2 8.4±0.3a 8.9±0.3b 7.4±0.1c 8.8±0.2 6.9±0.3d 8.3±0.2
P (mg/100 ml) 6.9±0.2 6.9±0.2 13.9±2.1b 15.7±2.5a 11.8±1.4 13.5±1.4 12.3±0.8 14.5±0.8
Ca P (mg2/(100 ml)2) 63±3 66±3 114±15b 135±16a 87±10 118±11 86±8 121±8
PTH (pg/ml) 113±12 126±18 1584±335a 1731±309a 545±169c 988±185 251±67d 793±62
BUN (mg/100 ml) ND 17±1 ND 103±38a ND 69±7 ND 70±4
Cr (mg/100 ml) ND 0.5±0.0 ND 1.6±0.4a ND 1.2±0.2 ND 1.0±0.1
1,25(OH)2VD (pg/ml) ND 48±12 ND 101±27 ND 79±16 ND 40±7
Osteocalcin (ng/ml) ND 24±2 ND 215±42a ND 165±29 ND 136±10
1,25(OH)2VD, 1,25-dihydroxyvitamin D3; BUN, blood urea nitrogen; Cr, creatinine; Ca, calcium; ND, not done; NX, nephrectomized; P, phosphorus; PTH, parathyroid hormone.
Blood was collected at 90 min and 24 h after the administration of cinacalcet at the end of the treatment period on day 41. Values are mean±s.e. (n¼ 11–12).
aPo0.01; bPo0.05 vs the sham-operated group; cPo0.05; dPo0.01 vs the NX-vehicle-treated group.
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Figure 1 | Aortic mineral content. Thoracic–abdominal aortae
were dissected and incinerated. The calcium (Ca) and phosphorus
(P) content of the resulting ash samples was then measured and
expressed as the weight of Ca or P per dry weight of tissue. The
aortic Ca and P content was found to have increased significantly
in nephrectomized (NX) rats. However, cinacalcet treatment
suppressed these increases. The values shown are the mean±s.e.
(n¼ 8–12). wwPo0.01 vs the NX baseline; ##Po0.01 vs the sham-
operated group; *Po0.05 vs the NX-vehicle-treated group.
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respectively, in the NX-vehicle-treated group compared with
the sham-operated group. However, cinacalcet treatment
reduced both the Ca and P levels in these animals (Figure 1).
Alizarin red staining showed calcification of the aortic arch in
the NX-vehicle-treated group, which displayed Mo¨nckeberg
arterial calcification, characterized by Ca deposition in the
medial smooth muscle cells (Figure 2). Cinacalcet treatment
suppressed Ca deposition around the medial smooth muscle
cells (Figure 2).
The tissue Ca and P content in the heart was also found to
be significantly increased in the NX-vehicle-treated group
compared with the sham-operated group (Figure 3). How-
ever, cinacalcet treatment reduced the Ca and P content in
the heart (Figure 3). By alizarin red staining, calcification of
the aortic root was evident in the NX-vehicle-treated group
but was suppressed by cinacalcet treatment (Figure 4). No
distinct Ca deposits could be observed in the cardiac muscle
cells by alizarin red staining.
Expression of calcification-related factors
The mRNA expression of osteoblastic markers, osteocalcin,
osteopontin, and runt-related gene 2 (Runx2) increased in
the aortae of NX-vehicle-treated rats compared with sham-
operated rats (Figure 5). The mRNA expression levels of these
proteins in NX-cinacalcet-treated rats were similar to those in
sham-operated rats. Expression of the osteocalcin and
osteopontin proteins was also increased in aortae of NX-
vehicle-treated rats, whereas no marked expression was
observed in aortae of NX-cinacalcet-treated rats (Figure 6).
The mRNA expression level of matrix Gla protein (MGP),
a calcification inhibitor, was also increased in NX rats
a b
c d
Figure 2 | Alizarin red staining of the aortic arch. (a) Sham-
operated rat; (b) NX-vehicle-treated rat; (c) cinacalcet-treated rat
(5 mg/kg); (d) cinacalcet-treated rat (15 mg/kg). Aortic arches were
stained with alizarin red. As indicated by the red staining, the
sections from nephrectomized (NX) rats showed calcification in
the medial smooth muscle cells, indicating the presence of
Mo¨nckeberg-type arterial calcification. No calcium deposits were
observed in the aortic tissues from animals treated with 15 mg/kg
cinacalcet (d) and only slight calcification was found in rats
treated with 5 mg/kg cinacalcet (c) (Original magnification,  40.)
0
1
2
3
4
(11)
(11)
(8) (8)(11) #
##
Ca
 (m
g/g
, d
ry 
we
igh
t)
Sham Vehicle  5 mg 15 mg Sham NX
NX Baseline
0
2
4
6
8
10
(11)
(11)
(8)(8)(11) ##
##
∗∗
P 
(m
g/g
, d
ry 
we
igh
t)
Sham Vehicle  5 mg 15 mg Sham NX
NX Baseline
Figure 3 | Heart mineral content. Dissected hearts were
incinerated, and the levels of calcium (Ca) and phosphorus (P)
content were then measured as described in Figure 1. In the
nephrectomized (NX)-vehicle-treated group, the heart Ca and P
content increased significantly, but this increase was suppressed
in both cases by cinacalcet treatment. The values shown are the
mean±s.e. (n¼ 8–12). #Po0.05; ##Po0.01 vs the sham-operated
group; *Po0.05 vs the NX-vehicle-treated group.
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Figure 4 | Alizarin red staining of the aortic valve. Dissected
aortic root tissues were stained with alizarin red. Sections from
nephrectomized (NX) rats show calcification, indicated by red
staining. No calcium deposits were detectable, however, in the
same tissues from animals treated with cinacalcet. (a) Sham-
operated rat; (b) NX-vehicle-treated rat; (c) cinacalcet-treated rat
(5 mg/kg); (d) cinacalcet-treated rat (15 mg/kg). (Original
magnification,  40.)
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compared with sham-operated rat (Figure 5). There was no
increase in MGP expression in the cinacalcet-treated NX rats.
The mRNA expression level of osteoprotegerin (OPG) was
similar among the groups (Figure 5).
Effects of PTX on tissue calcification
In NX-PTX rats, the body weights showed an even greater
decrease compared with NX-sham rats (data not shown).
Table 2 shows the results of serum parameter measurements
at day 69 after PTX. In the NX-sham rats, serum PTH, P,
Ca P product, and osteocalcin levels were elevated, whereas
the serum Ca levels decreased significantly compared with the
sham control rats. Serum PTH levels in NX-PTX animals
were below the detection limit. Serum levels of Ca P
product, 1,25(OH)2VD, and osteocalcin were also decreased
in NX-PTX rats compared with NX-sham rats. Moreover, the
serum Ca and P levels tended to show decreases following
PTX. The Ca and P content in the aorta increased
significantly in NX-sham rats compared with sham control
rats (Figure 7). In addition, compared with NX-sham rats,
the aortic Ca and P content in NX-PTX rats was at markedly
lower levels (Figure 7).
DISCUSSION
The results of our present study indicate that cinacalcet
treatment inhibits aortic calcification in NX rats that are
maintained on an HP-lactose chow. In addition, PTX also
suppressed aortic calcification in this animal model. Hence,
we postulate that cinacalcet can suppress aortic calcification
by decreasing the PTH level. We further found in the present
analyses that bone turnover was elevated in the NX-vehicle-
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Figure 5 | The mRNA expression of calcification-related
factors. Total RNA was isolated from rat aortae and reverse
transcribed to cDNA. The cDNA was quantified for osteocalcin
(OCN), osteopontin (OPN), runt-related gene 2 (Runx2), matrix Gla
protein (MGP), and osteoprotegerin (OPG). The aortic mRNA
expression levels of osteocalcin, osteopontin, Runx2, and MGP
were increased in the NX-vehicle-treated rats compared with the
sham-operated rats. Their expression levels in NX-cinacalcet-
treated rats were similar to those in sham-operated rats. The
values shown are the mean±s.e. (n¼ 5). #Po0.05 vs the sham-
operated group; *Po0.05 vs the NX-vehicle-treated group.
Sham NX + cinacalcetNX + vehicle
Osteocalcin
Osteopontin
Figure 6 | Osteocalcin and osteopontin protein expression in aortae. Histological sections of aortic arches were used for
immunostaining of osteocalcin and osteopontin. The protein expression of both osteocalcin and osteopontin was increased in the aortae of
NX-vehicle-treated rats (arrows), whereas no marked expression was observed in the aortae of NX-cinacalcet-treated rats. In each
photograph, the top side is intima and the bottom side is adventitia. (Original magnification,  400.)
Table 2 | Serum biochemical measurements (for PTX study)
Sham NX-sham NX-PTX
Ca (mg/100 ml) 8.8±0.1 7.0±0.5a 6.1±0.3
P (mg/100 ml) 5.8±0.1 16.7±3.4b 12.6±1.2
Ca P (mg2/(100 ml)2) 52±1 111±19b 77±8
PTH (pg/ml) 85±7 3216±925a 9±1c
BUN (mg/100 ml) 15±1 104±17a 63±10
Cr (mg/100 ml) 0.4±0.0 2.0±0.4a 1.2±0.2
1,25(OH)2VD (pg/ml) 57±13 43±10 4±1
c
Osteocalcin (ng/ml) 21±2 489±83a 79±7c
1,25(OH)2VD, 1,25-dihydroxyvitamin D3; BUN, blood urea nitrogen; Cr, creatinine;
Ca, calcium; NX, nephrectomized; PTX, parathyroidectomy; P, phosphorus; PTH,
parathyroid hormone.
Blood was collected at both 90 min and 24 h after treatment on day 68 post-PTX.
Values are the mean±s.e. (n=6).
aPo0.01; bPo0.05 vs the sham-control group; cPo0.01 vs the NX-sham group.
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treated rats, as evidenced by increased serum osteocalcin
levels. The evidence that cinacalcet decreases serum osteo-
calcin levels suggests that cinacalcet improves the deleterious
effects of accelerated bone turnover during 2HPT by
suppressing serum PTH levels. We speculate in this regard
that cinacalcet-induced decreases in serum PTH levels inhibit
the mobilization of Ca and P from the bone, thus suppressing
the induction of aortic calcification.
Even though the link between the elevation of bone
turnover and aortic calcification remains elusive, it is possible
that PTH might at least partially induce this calcification
process through such a mechanism.11 Clinical data show that
increased serum Ca, P, and Ca P product are associated
with an increased risk of cardiovascular disease.7,8,21 In
addition, vascular smooth muscle cells calcify when cultured
in vitro in medium containing high Ca or P.22,23 Findings
from previous studies as well as from our own suggest that
aortic calcification is accelerated by elevated serum Ca P
product, which is the result of an accelerated bone turnover
in 2HPT. In the present study, decreases in serum Ca, P, and
Ca P product were observed following both cinacalcet
treatment and PTX. These decreases, accompanied by a
reduction in serum PTH level, might contribute to the
suppression of aortic calcification.
It was reported previously that serum P levels tended to
increase with cinacalcet treatment in an NX rat model.19 On
the contrary, it has also been reported that serum P is
reduced by cinacalcet treatment in clinical studies.24 In NX
rats, it is thought that kidney function is maintained and that
renal P absorption is increased by the suppressive effects of
cinacalcet on serum PTH levels. In our present study, serum
P levels showed a tendency to decrease following cinacalcet
exposure. The inhibitory effects on the mobilization of P
from bone apparently overtake the increased levels of renal P
absorption by cinacalcet treatment.
The contribution of vitamin D to vascular calcification is a
well-established characteristic of 2HPT. Shalhoub et al.25
reported that 1,25(OH)2VD induces mineral deposition on
vascular smooth muscle cells in vitro. Thus, 1,25(OH)2VD
seems to have a direct effect on smooth muscle cells, causing
ectopic calcification. In the present study, cinacalcet tended
to decrease serum 1,25(OH)2VD levels in NX rats. It is
postulated that cinacalcet may inhibit aortic calcification, in
part by decreasing serum 1,25(OH)2VD levels.
There were significant increases in Runx2, osteocalcin, and
osteopontin gene expression in the NX rats; however, these
increased expressions were blocked in NX rats treated with
cinacalcet compared with sham-operated rats. It has been
reported that P and 1,25(OH)2VD induce Runx2 expression
and initiate mineralization of vascular smooth muscle cells.
RunX2 increases the expression of both osteocalcin and
osteopontin.23,25,26 The suppressive effect of cinacalcet on the
expression of these factors related to osteoblastic lineage, as
demonstrated in this study, may be linked to the result of
lowering of serum P and 1,25(OH)2VD level. It has been
reported that Ca receptor is expressed in both aortic smooth
muscle cells and endothelial cells.27 It should be further
elucidated whether the direct effect of cinacalcet on smooth
muscle cells might be to suppress the initiation of smooth
muscle cell calcification.
MGP and OPG are considered calcification inhibitors.
Further, it has been reported that MGP is increased by Ca in
vascular smooth muscle cells.28 However, in the present
study, the increased expression of MGP was associated with
calcified aortae of NX-vehicle-treated rats, suggesting that
this increased MGP expression might be the compensatory
action. In contrast to the NX-vehicle-treated rats, there was
no increase in the expression of MGP in NX-cinacalcet-
treated rats compared with sham-operated rats. There was
also no change in the expression of OPG in rats treated with
NX-vehicle or NX-cinacalcet compared with sham-operated
rats. Thus, it may be considered that these proteins, which
inhibit ectopic calcification, were not important in our study.
Three rats in the NX-vehicle group died during the course
of our current experiments. In contrast, all the NX rats
treated with cinacalcet survived and no deaths related to this
treatment were observed. Cinacalcet was also found to
suppress valvular and cardiac calcification. The progression
of aortic valvular calcification is associated with the risk of
cardiovascular disease and thus increases the risk of
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Figure 7 | Aortic mineral content in parathyroidectomized
(PTX) rats. The calcium (Ca) and phosphorus (P) content in the
aortae was found to increase significantly in nephrectomized (NX)
rats; however, PTX inhibited these increases. The values shown are
the mean±s.e. (n¼ 6). #Po0.05 vs the sham-operated group;
**Po0.01 vs the NX group.
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mortality. Our finding that no deaths occurred in the
cinacalcet treatment groups is encouraging because it further
suggests cinacalcet’s protective role during deleterious
cardiovascular events. Ogata et al.29 have reported that
calcimimetic R-568 has a protective effect against the
development of uremia and cardiovascular risk factors during
renal failure. Our finding that BUN levels tended to decrease
following both cinacalcet treatment and PTX suggests that
their protective effects against renal calcification might also
suppress development of uremia.
In summary, cinacalcet suppresses aortic calcification in
an NX rat model. Our current findings thus indicate the
potential of this drug for future treatments of aortic
calcification in dialysis patients diagnosed with 2HPT.
MATERIALS AND METHODS
Animal protocols
The experimental protocols used for the treatment of the subject rats
were approved by the Experimental Animal Ethical Committee of
Kirin Brewery Co., Ltd. The experimental schedule is outlined in
Figure 8. Sprague–Dawley rats (8-week old) were purchased from
Charles River Japan (Tokyo, Japan) and fed a standard diet (CE-2;
Clea Japan, Tokyo, Japan). These rats were allowed free access to
food and water; after an acclimatization period of 10 days, they were
divided into two groups that were matched with respect to body
weight. The rats in the uremic group comprised 5/6 nephrectomized
animals that were surgically treated under ether anesthesia. This
procedure involved removal of the right kidney and ligature of
branches of the left renal artery in a one-step procedure on day 15.
Sham operations were performed on the control animals. Two weeks
after the operations, the sham (n¼ 20) and the NX rats (n¼ 44)
were divided into two and four groups, respectively, which were
matched in terms of body weight and for serum Cr, Ca, P, PTH, and
BUN levels. The rats in the baseline groups (n¼ 8) were anesthetized
with ether, and blood was collected by means of an aortic puncture
on day 0. The aortic arch was then dissected and fixed in 10%
formalin for subsequent histological studies. The thoracic–abdom-
inal aorta was dissected and frozen for alizarin red staining to
quantify the aortic calcification levels.
To accelerate the process of aortic calcification, we used a high-
phosphate chow (Ca 1.0%, P 1.2%) containing 20% lactose (HP-
lactose chow), which facilitates intestinal Ca absorption in a vitamin
D-independent manner.30 Beginning on day 0, all treatment groups
(n¼ 12) were fed the HP-lactose chow. Two NX groups were
administrated cinacalcet orally once daily (5 or 15 mg/kg) for 41
days. Single sham and NX groups were treated with vehicle (0.5%
methylcellulose solution in distilled water). On day 42, blood
samples were collected 24 h after the last administration to measure
serum levels of Ca, P, BUN, Cr, PTH, 1,25(OH)2VD, and
osteocalcin. Serum levels of Ca, P, and PTH were also measured
90 min after the last administration on day 41. All rats were killed on
day 42 under the same procedures described for the baseline groups.
The aorta and heart from one NX rat in the vehicle-treated group
and one in the cinacalcet (15 mg/kg) group could not be used in the
study because the tissues were autolyzed.
PTX study
The experimental schedule for the PTX study is outlined in Figure 8.
Two weeks after the nephrectomies were performed, the NX rats
were divided into two groups matched by body weight, and by
serum levels of Cr, Ca, P, and BUN. One of these NX groups
underwent PTX, whereas the other NX group and a control group
were sham operated. PTX was performed under anesthesia. Briefly,
an incision was made in the neck region of the rats and the
5/6 Nx Autopsy
0 41–15
High phosphate and 20% lactose diet
Dosing period
Sham operated (n =12)
5/6 Nx + vehicle (n =12)
5/6 Nx + 5 mg/kg /day cinacalcet (n =12)
5/6 Nx + 15 mg/kg/day cinacalcet (n =12)
42 (days)–1
Assignment to experimental groups
Baseline autopsy (n =8)
Experimental groups
5/6 Nx Autopsy
–13 68 (days)–1
Assignment to experimental groups
Sham operated (n =6)
5/6 Nx-sham operated (n =6)
5/6 Nx-PTX operated (n =6)
Experimental groups
0
PTX
Cinacalcet study
PTX study
Figure 8 | Experimental design for the studies.
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parathyroid–thyroid complex was exposed under microscopy. The
parathyroid glands were then dissected out. The success of the PTX
procedure was determined on the basis of a fall of serum PTH levels
below the detection limit of a rat IRMA kit 1 day after the operation.
After PTX, all animals were fed the HP-lactose chow diet for 68 days.
After blood had been collected for serum parameter measurements,
these rats were killed, and their heart and aorta were dissected in
each case for the analysis of calcification.
Measurement of biochemical parameters
Serum levels of Ca, P, and BUN were measured with commercially
available kits (Wako Pure Chemical Industries, Ltd., Osaka, Japan).
Serum Cr was measured with an enzymatic assay (CRE-EN; Kainos
Laboratories, Tokyo, Japan). Serum PTH and osteocalcin levels were
measured with a rat PTH IRMA kit and a Rat Osteocalcin IRMA kit
(Immutopics, San Clemente, CA, USA), respectively. Serum
1,25(OH)2VD was measured with a 1,25(OH)2D RIA kit (TFB;
Immunodiagnostic System, Ltd., Boldon, UK).
Examination of calcification in aorta and heart
Aortic arches and hearts were fixed in 10% formalin, and
subsequently sectioned and stained with alizarin red to assess the
extent of mineralization. These thoracic–abdominal aortae and
hearts were dried and defatted in chloroform and methanol (2:1) for
48 h. The defatted samples were then dehydrated in acetone for 3 h
and incinerated to ashes at 550 1C for 12 h in an electronic muffle
furnace (KM-600; TOYOSEISAKUSYO Co., Ltd., Tokyo, Japan). The
resulting ash samples were then dissolved in hydrochloric acid
solution, diluted in distilled water, and subjected to measurement of
Ca and P concentrations. The Ca and P content in the aorta and the
heart was calculated as the weight of Ca and P per tissue dry weight
in each case.
Immunohistochemical analysis
After inactivation of intrinsic peroxidase by incubation in 3%
hydrogen peroxide diluted in methanol, the sections of aortic arches
were treated with skim milk to prevent background staining and
then incubated with anti-osteocalcin or anti-osteopontin rabbit
antibody (COSMO BIO, LSL, Tokyo, Japan) overnight at 4 1C in a
humidified chamber. After being rinsed, the sections were incubated
with biotinylated secondary antibody and peroxidase-conjugated
streptavidin, followed by visualization with vector-red or DAB
substrate kits (Vector Laboratories Inc., Burlingame, CA, USA), and
counterstained with hematoxylin.
Quantitative real-time PCR
Isogen reagent (Nippon Gene Co., Ltd., Tokyo, Japan) was used to
isolate total RNA from frozen aortae. The TaqMan reverse
transcription kit (Applied Biosystem, Foster City, CA, USA) was
used to reverse transcribe cDNA from total RNA. The cDNA was
quantified for octeocalcin, osteopontin, Runx2, MGP, and OPG. The
primer sets for osteocalcin (primer ID: RA009113), osteopontin
(primer ID: RA017345), MGP (primer ID: RA008628), and OPG
(primer ID: RA023599) were all purchased from TAKARA Bio Inc.,
Otsu, Japan. The primer sets for Runx2 were designed as follows:
50-ACTTCGTCAGCGTCCTATCAGTTC-30 (forward), 50-GCGTC
AACACCATCATTCTGG-30 (reverse). Samples were amplified in a
7900HT Fast Real-Time PCR system (Applied Biosystem), and the
results were corrected by normalization with the corresponding
levels of the internal control glyceraldehyde-3-phosphate dehydro-
genase, which was amplified by using primers purchased from
TAKARA Bio Inc. (primer ID: RA015380).
Statistical analysis
The differences between groups were compared by using the
Mann–Whitney U-test, and multiple comparisons were performed
with the Dunnett’s test. Differences with P-values of o0.05 were
accepted as statistically significant. All values are expressed as the
mean±s.e.
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